| Name | Title | Contact Details |
|---|---|---|
Thomas Kotarakos |
Senior Vice President, Finance | Profile |
Kristen Stants |
Chief People Officer | Profile |
At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
CoMentis is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.